Evidence map›Paper›PMID 31083605›Full record

ArticleBiomolecules2019

Combinatorial Use of Chitosan Nanoparticles, Reversine, and Ionising Radiation on Breast Cancer Cells Associated with Mitosis Deregulation.

Sofia Piña Olmos, Roberto Díaz Torres, Eman Elbakrawy, Louise Hughes, Joseph Mckenna, Mark A Hill, Munira Kadhim, Patricia Ramírez Noguera, Victor M Bolanos-Garcia

Open access · goldAbstract read
In one paragraph

Article in Biomolecules, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. A Nanorobotics-Based Approach of Breast Cancer in the Nanotechnology Era.International journal of molecular sciences · 2024
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Sofia Piña OlmosLaboratorio de Toxicología Celular L-9, Unidad de Investigación Multidisciplinaria UNAM, FES-Cuautitlán. Campo 4. Carretera Cuautitlán-Teoloyucan Km 2.5, San Sebastián Xhala, Cuautitlán Izcalli, Estado de México 54719, Mexico. spina@comunidad.unam.mx.ORCID 0000-0002-3020-988X
Roberto Díaz TorresLaboratorio de Toxicología Celular L-9, Unidad de Investigación Multidisciplinaria UNAM, FES-Cuautitlán. Campo 4. Carretera Cuautitlán-Teoloyucan Km 2.5, San Sebastián Xhala, Cuautitlán Izcalli, Estado de México 54719, Mexico. diaztorres_r@hotmail.com.
Eman ElbakrawyDepartment of Biological and Medical Sciences, Faculty of Health and Life Sciences, Oxford Brookes University, Gipsy Lane, Headington, Oxford OX3 0BP, UK. eelbakrawy@brookes.ac.uk.
Louise HughesDepartment of Biological and Medical Sciences, Faculty of Health and Life Sciences, Oxford Brookes University, Gipsy Lane, Headington, Oxford OX3 0BP, UK. louise.hughes@oxinst.com.ORCID 0000-0002-7505-202X
Joseph MckennaDepartment of Biological and Medical Sciences, Faculty of Health and Life Sciences, Oxford Brookes University, Gipsy Lane, Headington, Oxford OX3 0BP, UK. josephmckenna@brookes.ac.uk.ORCID 0000-0003-4838-6048
Mark A HillCRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, ORCRB Roosevelt Drive, Oxford OX3 7DQ, UK. mark.hill@oncology.ox.ac.uk.ORCID 0000-0002-6894-7829
Munira KadhimDepartment of Biological and Medical Sciences, Faculty of Health and Life Sciences, Oxford Brookes University, Gipsy Lane, Headington, Oxford OX3 0BP, UK. mkadhim@brookes.ac.uk.
Patricia Ramírez NogueraLaboratorio de Toxicología Celular L-9, Unidad de Investigación Multidisciplinaria UNAM, FES-Cuautitlán. Campo 4. Carretera Cuautitlán-Teoloyucan Km 2.5, San Sebastián Xhala, Cuautitlán Izcalli, Estado de México 54719, Mexico. ramireznoguera@unam.mx.
Victor M Bolanos-GarciaDepartment of Biological and Medical Sciences, Faculty of Health and Life Sciences, Oxford Brookes University, Gipsy Lane, Headington, Oxford OX3 0BP, UK. vbolanos-garcia@brookes.ac.uk.ORCID 0000-0003-2700-1479
Oxford Brookes University · GBUniversidad de Cuautitlán Izcalli · MXUniversity of Oxford · GB

Funding

Medical Research Council MC_U142760473
6 · The paper itself

Abstract

Breast cancer is the most commonly occurring cancer in women worldwide and the second most common cancer overall. The development of new therapies to treat this devastating malignancy is needed urgently. Nanoparticles are one class of nanomaterial with multiple applications in medicine, ranging from their use as drug delivery systems and the promotion of changes in cell morphology to the control of gene transcription. Nanoparticles made of the natural polymer chitosan are easy to produce, have a very low immunogenic profile, and diffuse easily into cells. One hallmark feature of cancer, including breast tumours, is the genome instability caused by defects in the spindle-assembly checkpoint (SAC), the molecular signalling mechanism that ensures the timely and high-fidelity transmission of the genetic material to an offspring. In recent years, the use of nanoparticles to treat cancer cells has gained momentum. This is in part because nanoparticles made of different materials can sensitise cancer cells to chemotherapy and radiotherapy. These advances prompted us to study the potential sensitising effect of chitosan-based nanoparticles on breast cancer cells treated with reversine, which is a small molecule inhibitor of Mps1 and Aurora B that induces premature exit from mitosis, aneuploidy, and cell death, before and after exposure of the cancer cells to X-ray irradiation. Our measurements of metabolic activity as an indicator of cell viability, DNA damage by alkaline comet assay, and immunofluorescence using anti-P-H3 as a mitotic biomarker indicate that chitosan nanoparticles elicit cellular responses that affect mitosis and cell viability and can sensitise breast cancer cells to X-ray radiation (2Gy). We also show that such a sensitisation effect is not caused by direct damage to the DNA by the nanoparticles. Taken together, our data indicates that chitosan nanoparticles have potential application for the treatment of breast cancer as adjunct to radiotherapy.

Indexed as

Antineoplastic AgentsAurora Kinase BCell Cycle ProteinsChitosanHumansMCF-7 CellsMitosisMorpholinesNanoparticlesProtein Serine-Threonine KinasesProtein-Tyrosine KinasesPurinesX-Rays2-(4-morpholinoanilino)-6-cyclohexylaminopurineAntineoplastic AgentsAurora Kinase BCell Cycle ProteinsChitosanMorpholinesProtein Serine-Threonine KinasesProtein-Tyrosine KinasesPurinesTTK protein, humanbreast cancermitosis deregulationnanoparticlesspindle-assembly checkpoint inhibitiontumour sensitisation

Identifiers

PMID31083605
PMCPMC6571805
OpenAlexW2944503403

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.